Sign In
Buy QTRX
$3.22
-0.270 (-7.74%)
At Close: Jun 23, 2026
Quanterix To Report First Quarter 2024 Financial Results
04:00pm, Monday, 29'th Apr 2024
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conferen
Quanterix Outlines Partner Path With Labs to Expedite Building Global Alzheimer's Disease Testing Infrastructure
05:30pm, Thursday, 21'st Mar 2024
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a leading provider of ultra-sensitive research products and high-definition diagnostics, today announced a specific partnership
Quanterix (QTRX) AD Offering Gets FDA's Breakthrough Device Tag
10:51am, Wednesday, 06'th Mar 2024
Quanterix's (QTRX) blood-based biomarker test offers a non-invasive alternative, potentially revolutionizing how AD is diagnosed and managed.
Quanterix Granted Breakthrough Device Designation from U.S. FDA for Blood-Based p-Tau 217 Test for Alzheimer's Disease
09:00am, Monday, 04'th Mar 2024
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a leading provider of ultra-sensitive research products and high-definition diagnostics, announced today that its Simoa® phosp
Quanterix Corporation (QTRX) Reports Q4 Loss, Tops Revenue Estimates
06:11pm, Thursday, 29'th Feb 2024
Quanterix Corporation (QTRX) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.50 per share a year ago.
Quanterix Releases Operating Results for Fourth Quarter and Full Year 2023
04:00pm, Thursday, 29'th Feb 2024
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the fo
Quanterix (QTRX) Expands in Alzheimer's Testing With Alliances
11:06am, Tuesday, 27'th Feb 2024
Quanterix's (QTRX) blood-based biomarker testing offers a superior alternative, aligning with the recommendations of the NIA-AA criteria for AD diagnosis.
Quanterix Reschedules Q4 and Full Year 2023 Earnings Conference Call; Reaffirms 2023 Guidance
06:58pm, Monday, 26'th Feb 2024
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX) today announced that it has rescheduled the release of its financial results for the fourth quarter and year ended December 31,
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a leading provider of ultra-sensitive research products and high-definition diagnostics, today announced its first collaboratio
Quanterix to Present at Cowen's 44th Annual Health Care Conference
04:30pm, Friday, 23'rd Feb 2024
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer
Quanterix Fourth Quarter Earnings and Full Year 2023 Financial Results Conference Call
04:00pm, Friday, 16'th Feb 2024
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced it will host a conference ca
Quanterix to Present at 42nd Annual J.P. Morgan Healthcare Conference
04:00pm, Tuesday, 12'th Dec 2023
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that President and Chief Exe
Here's Why Quanterix Corporation (QTRX) is a Great Momentum Stock to Buy
01:32pm, Monday, 04'th Dec 2023
Does Quanterix Corporation (QTRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Does Quanterix Corporation (QTRX) Have the Potential to Rally 33.74% as Wall Street Analysts Expect?
11:17am, Wednesday, 29'th Nov 2023
The mean of analysts' price targets for Quanterix Corporation (QTRX) points to a 33.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement
Quanterix To Participate at The Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
04:00pm, Monday, 13'th Nov 2023
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that President and Chief Exe
